Pathogenesis of Nigral Cell Death in Parkinson’s Disease

  • Y. Mizuno
  • S. Ikebe
  • N. Hattori
  • H. Mochizuki
  • K. Nishi
  • H. Yoshino
  • T. Kondo
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

During the past several years, several important findings which may play a role in the degeneration of nigral cell in Parkinson’s disease (PD) have been disclosed (Table 1). In this review, we will critically discuss the significance and implications of those findings including the question as to whether those findings are the primary defects or the secondary effects of an as yet undiscovered primary abnormality in PD. In Parkinson’s disease, we cannot dismiss secondary abnormalities as they may interfere with the regenerative and restorative processes, and may contribute to the progression of the disease. We would like to start our discussion with iron accumulation in Parkinson’s disease.

Keywords

Tyrosine Hydroxylase Substantia Nigra Monoamine Oxidase Iron Accumulation Parkinson Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Collins, M.A., and Neafsey, E., 1985, ß-Carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci. Lett. 55: 179–184.PubMedCrossRefGoogle Scholar
  2. Corral-Debrinski, M., Horton, T., Lou, M.T., Shoffner, J.M., Beal, M.F., and Wallace, D., 1992, Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age, Nature Genetics, 2: 324–329.PubMedCrossRefGoogle Scholar
  3. Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., and Marsden, C.D., 1989, Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease, J. Neurochem. 52: 381–389.PubMedCrossRefGoogle Scholar
  4. Halliwell, B., 1989, Oxidants and the central nervous system: some fundamental questions, Acta Neurol. Scand. 126: 23–33.CrossRefGoogle Scholar
  5. Hattori, N., Tanaka, M., Ozawa, T., and Mizuno, Y., 1991, Immunohistochemical studies on Complexes I, II, III, and IV of mitochondria in Parkinson’s disease, Ann. Neurol. 30: 563–571.PubMedCrossRefGoogle Scholar
  6. Ikebe, S., Tanaka, M., Ohno, K., Sato, W., Hattori, K., Kondo, T., Mizuno, Y., and Ozawa, T., 1990, Increase of deleted mitochondrial DNA in the striatum in Parkinson’s disease and senescence, Biochem. Biophys. Res. Commun. 170: 1044–1048.PubMedCrossRefGoogle Scholar
  7. Ikebe, S., Hattori, N., Mizuno, Y., Tanaka, M., and Ozawa, T., 1992, Point mutations of mitochondrial DNA in Parkinson’s disease, Abst. Mov. Disord. 7, Supp1. 1: 71.Google Scholar
  8. Jenner, P., Dexter, D.T., Sian, J., Schapira, A.H.V., and Marsden, C.D., 1992, Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental Lewy body disease, Ann. Neurol. 32: S82 - S87.PubMedCrossRefGoogle Scholar
  9. Kurth, J.H., Kurth, M.C., Poduslo, S.E., and Schwankhaus, J.D., 1993, Association of a monoamine oxidase B allele with Parkinson’s disease, Ann. Neurol. 33: 368–372.PubMedCrossRefGoogle Scholar
  10. Lestienne, P., Nelson, J., Riederer, P., Jellinger, K., and Reichmann, H., 1990, Normal mitochondrial genome in brain from patients with Parkinson’s disease and complex I defect, J. Neurochem. 55: 1810–1812.PubMedCrossRefGoogle Scholar
  11. Linnane, A.W., Marzuki, S., Ozawa, T., and Tanaka, M.,1989, Mitochondria) DNA mutations as an important contributor to ageing and degenerative diseases, Lancet 1: 642–645.Google Scholar
  12. Marttila, R.J., Lorentz, H., and Rinne, U.K., 1988, Oxygen toxicity protecting enzymes in Parkinson’s disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus, J. Neurol. Sci. 86: 321–331.PubMedCrossRefGoogle Scholar
  13. Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., Sato, T., Oya, H., Ozawa, T., and Kagawa, Y., 1989, Deficiencies in Complex I subunits of the respiratory chain in Parkinson’s disease, Biochem. Biophys. Res. Commun. 163: 1450–1455.PubMedCrossRefGoogle Scholar
  14. Mizuno, Y., Matuda, S., Yoshino, H., Mori, H., Hattori, N., and Ikebe, S., 1993, An immuno-histochemic al study on a-ketoglutarate dehydrogenase complex in Parkinson’s disease. Ann. Neurol., in press.Google Scholar
  15. Mochizuki, H., Nishi, K., and Mizuno, Y., 1993, Iron-melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture, Neurodegeneration 2: 1–7.Google Scholar
  16. Moll, G., Moll, R, Riederer, P., Gsell, W., Heinsen, H., and Denney, R.M., 1990, Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pilot study, J. Neural. Transm. Suppl. 32: 67–77.Google Scholar
  17. Nagatsu, T., and Yoshida, M.,1988, An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterine in the nigrostriatal regions, Neurosci. Lett. 87: 178–182.Google Scholar
  18. Naoi, M., Takahashi, T., Parvez, H., Kabeya, R., Taguchi, E., Yamaguchi, K., Hirata, Y., Minami, M., and Nagatsu, Y., 1989, N-methylisoquinolinium ion as an inhibitor of tyrosine hydroxylase, aromatic Lamino acid decarboxylase and monoamine oxidase, Neurochem. Int. 15: 315–320.PubMedCrossRefGoogle Scholar
  19. Perry, T.L., and Yong, V.W., 1986, Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients, Neurosci. Lett. 67: 269–274.PubMedCrossRefGoogle Scholar
  20. Philbert, M.A., Beiswanger, C.M., Waters, D.K., Reuhl, K.R., and Lowndes, H.E., 1991, Cellular and regional distributions of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-phthalaldehyde-induced histofluorescence, Toxicol. App. Pharmacol. 107: 215–227.CrossRefGoogle Scholar
  21. Riederer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K., and Youdim, M.B.H., 1989, Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J. Neurochem. 52: 515–520.PubMedCrossRefGoogle Scholar
  22. Saggu, H., Cooksey, J., Dexter, D., Wells, F.R., Lees, A., Jenner, P., and Marsden, C.D., 1989, A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra, J. Neurochem. 53: 692–697.PubMedCrossRefGoogle Scholar
  23. Sandler, M., Carter, S.B., Hunter, K.R., and Stern, G.M., 1973, Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man, Nature 241: 439–443.PubMedCrossRefGoogle Scholar
  24. Schapira, A.H.V., Cooper, J.M., Dexter, D., Jenner, P., Clark, J.B., and Marsden, C.D., 1989, Mitochondrial complex I deficiency in Parkinson’s disease, Lancet 1: 1269.PubMedCrossRefGoogle Scholar
  25. Schapira, A.H.V., Holt, U., Sweeney, M., Harding, A.E., Jenner, P., and Marsden, C.D.,1990, Mitochondrial DNA analysis in Parkinson’s disease, Mov. Disord. 5: 294–297.Google Scholar
  26. Shoffner, J.M., Brown, M.D., Torroni, A., Lott, M.T., Cabell, M.F., Mirra, S.S., Beal, M.F., Yang, C.C., Gearing, M., Salvo, R., Watts, R.L., Juncos, J.L., Hansen L.A., Crain, B.J., Fayad, M., Reckord, C.L., and Wallace, D.C., 1993, Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients, Genomics 17: 171–184.PubMedCrossRefGoogle Scholar
  27. Smith, C.A., Gough, A.C., Leigh, P.N., Summers, B.A., Harding, A.E., Maranganore, D.M., Sturman, S.G., Schapira, A.V., Williams, A.C., Spun, N.K., and Wolf, C.R., 1992, Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease, Lancet 339: 1375–1377.PubMedCrossRefGoogle Scholar
  28. Soong, K., Hinton, D.R., Cortopassi, G., and Arnheim, N., 1992, Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain, Nature Genetics 2: 318–323.PubMedCrossRefGoogle Scholar
  29. Suzuki, K., Mizuno, Y., and Yoshida, M., 1990, Inhibition of mitochondrial respiration by 1,2,3,4tetrahydroisoquinoline-like endogenous alkaloids in mouse brain, Neurochem. Res. 15: 705–710.PubMedCrossRefGoogle Scholar
  30. Suzuki, K., Mizuno, Y., Yamauchi, Y., Nagatsu, T., and Yoshida, M., 1992, Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain, J.Neurol. Sci. 109: 219–223.PubMedCrossRefGoogle Scholar
  31. Youdim, M.B.H., Ben-Shachar, D., and Riederer, P. 1989, Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in ion and melanin induced neurodegeneration? Acta Neurol. Scand., 126: 47–54.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Y. Mizuno
    • 1
  • S. Ikebe
    • 1
  • N. Hattori
    • 1
  • H. Mochizuki
    • 1
  • K. Nishi
    • 1
  • H. Yoshino
    • 1
  • T. Kondo
    • 1
  1. 1.Department of NeurologyJuntendo University School of MedicineBunkyo, Tokyo 113Japan

Personalised recommendations